---
title: https://www.patentvest.com/patentvest-pulse/the-amylin-renaissance-forty-programs-19-billion-in-deals-and-the-race-to-build-the-next-pillar-of-obesity-medicine/
---

[Skip to content](https://insights.patentvest.com/https/www.patentvest.com/patentvest-pulse/the-amylin-renaissance-forty-programs-19-billion-in-deals-and-the-race-to-build-the-next-pillar-of-obesity-medicine#main-content)

[![](https://insights.patentvest.com/hubfs/Artboard%201.svg)](https://www.patentvest.com/)

- [Why PatentVest](https://www.patentvest.com/why-patentvest/)
- [Our Solution](https://www.patentvest.com/our-solution/)
- [About Us](https://www.patentvest.com/about-us/)
  
  Show submenu for About Us 
  
    - [About PatentVest](https://www.patentvest.com/about-us/)
    - [Our Team](https://www.patentvest.com/about-us/our-team/)
    - [Our Track Record](https://www.patentvest.com/about-us/our-track-record/)
- [Contact Us](https://www.patentvest.com/contact-us/)

Open main navigation

Close main navigation

- [Why PatentVest](https://www.patentvest.com/why-patentvest/)
- [Our Solution](https://www.patentvest.com/our-solution/)
- [About Us](https://www.patentvest.com/about-us/)
  
  Show submenu for About Us 
  
    - [About PatentVest](https://www.patentvest.com/about-us/)
    - [Our Team](https://www.patentvest.com/about-us/our-team/)
    - [Our Track Record](https://www.patentvest.com/about-us/our-track-record/)
- [Contact Us](https://www.patentvest.com/contact-us/)

## PATENTVEST PULSE REPORT

## The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine

By filling out this form, you’ll get instant access to our exclusive report, revealing who will control the second wave of the $100B+ obesity market as Amylin emerges beyond GLP-1.

 

### To access this report, please complete the form below

## **You’ll get instant access to our exclusive report revealing:**

- Why Amylin, once abandoned after early failures,  is now the only validated mechanism that can push weight loss beyond GLP-1’s ceiling.
- How 40+ amylin programs across peptides, small molecules, and antibodies are competing to define the next standard of care.
- The breakthrough behind GLP-1 + amylin combinations, delivering ~20%+ weight loss and unlocking a new treatment tier for non-responders.
- What $19B+ in deal activity (Pfizer, Roche, AbbVie, Novo Nordisk, Eli Lilly) reveals about where Big Pharma is placing its next bets.
- The programs that matter most — from CagriSema and eloralintide to petrelintide and oral small-molecule entrants.
- Why tolerability,  not just efficacy,  may determine the winners, with next-gen drugs achieving “placebo-like” safety profiles.
- How oral small-molecule amylin agonists could replicate the GLP-1 playbook and unlock the 95% of patients who won’t inject.
- Why the real competitive moat isn’t clinical data,  it’s patent architecture, exclusivity timelines, and freedom-to-operate positioning.

---

 

[![](https://insights.patentvest.com/hubfs/Artboard%201.svg)](https://www.patentvest.com/)

[LinkedIn](https://www.linkedin.com/company/patentvest-inc.)